Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - rosuvastatin (as calcium) - film-coated tablet - 10mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - rosuvastatin (as calcium) - film-coated tablet - 20mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: biocare lifesciences, inc. - hydrocortisone (as sodium succinate) - powder for injection (im/iv) - 100mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - rabeprazole (as sodium) - powder for injection (iv) - 20mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: biocare lifesciences, inc. - co-amoxiclav - powder for oral suspension - 228.5mg/ 5ml

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: biocare lifesciences inc. - co-amoxiclav - film-coated tablet - 375mg

Philippines - English - FDA (Food And Drug Administration)

biocare lifesciences, inc.; distributor: biocare lifesciences, inc. - clopidogrel (as bisulfate) - film-coated tablet - 75mg

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - primidone (unii: 13afd7670q) (primidone - unii:13afd7670q) - primidone 50 mg - primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. it may control grand mal seizures refractory to other anticonvulsant therapy. primidone is contraindicated in: 1) patients with porphyria and 2) patients who are hypersensitive to phenobarbital (see clinical pharmacology ).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease